Nurix Therapeutics (NRIX): Q1 2026 Earnings Reflect Pipeline Investment Amid Revenue Dip
Key Takeaways
- Nurix Therapeutics reported fiscal first quarter 2026 revenue of $6.3 million, down from $18.5 million a year ago due to the end of initial research terms in the Sanofi collaboration.
- Net loss widened to $87.2 million, or ($0.79) per share, compared to $56.4 million, or ($0.67) per share, in the prior-year quarter; EPS missed consensus estimates of ($0.76).
- Revenue of $6.3 million significantly trailed expectations of about $14.25 million, reflecting lower collaboration income.
- R&D expenses rose to $84.1 million from $69.7 million, driven by clinical trial acceleration for bexobrutideg in chronic lymphocytic leukemia (CLL).
- Cash, cash equivalents, and marketable securities stood at $540.7 million as of February 28, 2026, supporting ongoing programs.
- Key pipeline advances include ongoing Phase 2 enrollment for bexobrutideg and planned Phase 3 initiation by mid-2026.
Earnings Context and Why It Matters
As I review Nurix Therapeutics (NRIX)' fiscal first quarter 2026 results, covering the period ended February 28, 2026, it's clear the company is doubling down on its targeted protein degradation therapies for cancer and inflammatory diseases. For a pre-commercial biopharma like this, the real value lies in clinical milestones, such as the potential accelerated approval of bexobrutideg in relapsed/refractory CLL. The revenue drop and wider loss highlight the R&D ramp-up, but with cash extending into 2028, Nurix has runway to execute. In my view, success will depend on trial progress and partnerships with Gilead, Sanofi, and Pfizer amid a tough biotech environment.
Reported Results
Collaboration revenue came in at $6.3 million for the quarter, a sharp decline from $18.5 million last year, primarily because initial research terms for certain targets in the Sanofi partnership wrapped up. This missed the consensus estimate of around $14.25 million. I also checked this using Tickeron’s AI Screener to see how NRIX stacks up against peers on revenue trends.
R&D expenses increased to $84.1 million from $69.7 million year-over-year, driven by higher personnel costs, expanded clinical trials, and manufacturing for the bexobrutideg program. General and administrative costs rose to $14.6 million from $11.7 million, largely from personnel-related expenses.
The net loss grew to $87.2 million, or ($0.79) per share, compared to $56.4 million, or ($0.67) per share, in the prior year. EPS missed the analyst consensus of ($0.76). The company didn't update specific guidance but highlighted ongoing pipeline momentum.
Market Reaction and Investor Sentiment
After the April 8, 2026, earnings release, NRIX shares had a mixed response, up about 3% in pre-market before settling. By April 14, the stock traded around $16.30, with investors focusing more on pipeline news than the revenue shortfall or loss expansion. Year-to-date performance has faced biotech sector headwinds, yet analysts hold a positive stance, with an average price target of $30.24. From what I see, sentiment is tied to clinical delivery over short-term financials.
Forward Outlook and Key Factors to Monitor
The path ahead for Nurix centers on bexobrutideg (NX-5948), with Phase 2 DAYBreak CLL-201 enrollment progressing in relapsed/refractory CLL patients who've progressed after cBTKi, BCL-2 inhibitor, and non-covalent BTK inhibitor therapies. This single-arm study could support accelerated approval, and I'm watching for topline data at 2026 medical meetings.
Mid-2026 brings the start of the global Phase 3 DAYBreak CLL-306 trial, pitting bexobrutideg against pirtobrutinib for full approval. Phase 1b cohorts are testing higher doses in earlier CLL lines, with updates expected through the year.
In immunology, a new tablet formulation is advancing toward a 2026 IND filing. Partnerships are key: Sanofi's STAT6 degrader NX-3911 approaches IND-enabling studies, Gilead's IRAK4 degrader GS-6791 has entered Phase 1, and the Pfizer collaboration continues to deliver milestones. The $540.7 million cash pile as of February 28 funds operations without near-term dilution.
One thing that stands out is the need to monitor trial enrollment, safety profiles, milestone payments, and broader biotech funding trends. Profitability remains distant, with clinical catalysts driving the story.
Discovering Opportunities with Tickeron’s AI Screener
In my own research process, I rely on Tickeron’s AI Screener to sift through stocks and ETFs using technical patterns, fundamentals, trends, volatility, and AI signals. It lets me apply customizable filters like industry, market cap, indicators, price patterns, and performance metrics to spot trade ideas, breakouts, and opportunities faster than manual methods. This tool has become essential for efficiently scanning the biotech space and refining my watchlist—worth exploring to sharpen your strategy.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
Contributor
Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.
NRIX's RSI Oscillator descends into oversold zone
The RSI Indicator for NRIX moved into overbought territory on October 05, 2026. Be on the watch for a price drop or consolidation in the future -- when this happens, think about selling the stock or exploring put options.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
Following a +0.17% 3-day Advance, the price is estimated to grow further. Considering data from situations where NRIX advanced for three days, in 206 of 251 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
NRIX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on September 21, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on NRIX as a result. In 70 of 85 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 82%.
NRIX moved below its 50-day moving average on September 23, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for NRIX crossed bearishly below the 50-day moving average on September 23, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 11 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 85%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NRIX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
The Aroon Indicator for NRIX entered a downward trend on October 05, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 38 (best 1 - 100 worst), indicating steady price growth. NRIX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 47 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.101) is normal, around the industry mean (26.780). P/E Ratio (0.000) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (68.493) is also within normal values, averaging (438.009).
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NRIX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a biopharmaceutical company, which focuses on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders
Industry Biotechnology
Advertisement